FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the ...
Ono Pharmaceutical’s vimseltinib to treat tenosynovial giant cell tumour gets US FDA approval: Osaka Friday, February 21, 2025, 15:00 Hrs [IST] Ono Pharmaceutical, one of the la ...
Oxysterols are a class of molecules derived from cholesterol via oxidation or as byproducts of cholesterol synthesis.
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat adults with ...
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback